OSTX Rises as OS Therapies Reports 72.7% Three-Year Survival in Phase 2b Metastatic Osteosarcoma Study
Market Chameleon (Tue, 6-Oct 10:28 AM)
OSTX Gains FDA Alignment on Phase 3 Adaptive Design as MHRA Leads Project Orbis for OST-HER2
Market Chameleon (Thu, 17-Sep 10:26 AM)
